The DOI matches its Crossref record; 52 of the 54 references it cites were found in a registry or an index.
GLP-1 Receptor Agonist Treatment Increases Bone Formation and Prevents Bone Loss in Weight-Reduced Obese Women
Abstract
CONTEXT: Recent studies indicate that glucagon-like peptide (GLP)-1 regulates bone turnover, but the effects of GLP-1 receptor agonists (GLP-1 RAs) on bone in obese weight-reduced individuals are unknown. OBJECTIVE: To investigate the role of GLP-1 RAs on bone formation and weight loss-induced bone mass reduction. DESIGN: Randomized control study. SETTING: Outpatient research hospital clinic. PARTICIPANTS: Thirty-seven healthy obese women with body mass index of 34 ± 0.5 kg/m(2) and age 46 ± 2 years. INTERVENTION: After a low-calorie-diet-induced 12% weight loss, participants were randomized to treatment with or without administration of the GLP-1 RA liraglutide (1.2 mg/d) for 52 weeks. In case of weight gain, up to two meals per day could be replaced with a low-calorie-diet product to maintain the weight loss. MAIN OUTCOME MEASURES: Total, pelvic, and arm-leg bone mineral content (BMC) and bone markers [C-terminal telopeptide of type 1 collagen (CTX-1) and N-terminal propeptide of type 1 procollagen (P1NP)] were investigated before and after weight loss and after 52-week weight maintenance. Primary endpoints were changes in BMC and bone markers after 52-week weight maintenance with or without GLP-1 RA treatment. RESULTS: Total, pelvic, and arm-leg BMC decreased during weight maintenance in the control group (P < .0001), but not significantly in the liraglutide group. Thus, total and arm-leg BMC loss was four times greater in the control group compared to the liraglutide group (estimated difference, 27 g; 95% confidence interval, 5-48; P = .01), although the 12% weight loss was maintained in both groups. In the liraglutide group, the bone formation marker P1NP increased by 16% (7 ± 3 μg/L) vs a 2% (-1 ± 4 μg/L) decrease in the control group (P < .05). The bone resorption marker CTX-1 collagen did not change during the weight loss maintenance phase. CONCLUSIONS: Treatment with a long-acting GLP-1 RA increased bone formation by 16% and prevented bone loss after weight loss obtained through a low-calorie diet, supporting its role as a safe weight-lowering agent.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In euglycemic individuals, liraglutide increased procollagen type I N-terminal propeptide (P-PINP) levels by 16%, compared with a 2% decrease in the placebo group [42].”
From Nutrition and Physical Activity in Optimizing Weight Loss and Lean Mass Preservation in the Incretin-Based Medications Era: A Narrative Review (2025) · cites this paper as [42]
In the citing paper
“Treatment with liraglutide has been shown to increase bone formation in body weight-reduced obese women when compared to placebo (14).”
In the citing paper
“The reduction in PINP in the exenatide-treated group contrasts a previously reported increase of PINP in obese women, who experienced a 12% body weight reduction after 12 months of liraglutide treatment (14).”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371
Self-citationBone “mass” and the “mechanostat”: A proposal
Frost, H. M. (1987) · The Anatomical Record · doi:10.1002/ar.1092190104 · Cited by 2,132
Systematic Review of Type 1 and Type 2 Diabetes Mellitus and Risk of Fracture
Janghorbani, M., van Dam, R. M., Willett, W. C., & Hu, F. B. (2007) · American Journal of Epidemiology · doi:10.1093/aje/kwm106 · Cited by 1,223
for the IOF-IFCC Bone Marker Standards Working Group, Vasikaran, S., Eastell, R., Bruyère, O., Foldes, A. J., Garnero, P., Griesmacher, A., McClung, M., Morris, H. A., Silverman, S., et al. (2011) · Osteoporosis International · doi:10.1007/s00198-010-1501-1 · Cited by 1,212
Astrup, A., Rössner, S., Van Gaal, L., Rissanen, A., Niskanen, L., Al Hakim, M., Madsen, J., Rasmussen, M. F., & Lean, M. E. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61375-1 · Cited by 1,163
Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis
Loke, Y. K., Singh, S., & Furberg, C. D. (2008) · Canadian Medical Association Journal · doi:10.1503/cmaj.080486 · Cited by 553
Mechanical and textural properties of pelvic trabecular bone
Dalstra, M., Huiskes, R., Odgaard, A., & van Erning, L. (1993) · Journal of Biomechanics · doi:10.1016/0021-9290(93)90014-6 · Cited by 361
Bone Metabolism in Obesity and Weight Loss
Shapses, S. A., & Sukumar, D. (2012) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.012809.104655 · Cited by 358
Role of Gastrointestinal Hormones in Postprandial Reduction of Bone Resorption
Henriksen, D. B., Alexandersen, P., Bjarnason, N. H., Vilsbøll, T., Hartmann, B., Henriksen, E. E., Byrjalsen, I., Krarup, T., Holst, J. J., & Christiansen, C. (2003) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2003.18.12.2180 · Cited by 331
Self-citationFærch, K., Torekov, S. S., Vistisen, D., Johansen, N. B., Witte, D. R., Jonsson, A., Pedersen, O., Hansen, T., Lauritzen, T., Sandbæk, A., et al. (2015) · Diabetes · doi:10.2337/db14-1751 · Cited by 321
Self-citation
Research works printed but not linked: 1
- Henriksen DB, Alexandersen P, Bjarnason NH, et al. Role of gas- trointestinal hormones in postprandial reduction of bone resorp- tion. J Bone Miner Res. 2003;18(12):2180 -2189.
Cited by
Sorted by citations
Items 101–191 of 191
Pahk, K., Kwon, Y., Kim, M.-K., Park, S. S., & Kim, S. (2020) · Obesity Research & Clinical Practice · doi:10.1016/j.orcp.2020.05.008 · Cited by 16
Adults with pathogenic MC4R mutations have increased final height and thereby increased bone mass
Iepsen, E. W., Zhang, J., Hollensted, M., Madsbad, S., Hansen, T., Holst, J. J., Jørgensen, N. R., Holm, J.-C., & Torekov, S. S. (2020) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-019-01034-8 · Cited by 15
Self-citationThe effects of anti‐obesity medications on bone metabolism: A critical appraisal
Anastasilakis, A. D., Paccou, J., Palermo, A., & Pοlyzos, S. A. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16541 · Cited by 18
Hsu, Y.-H., Liang, Y.-C., Chan, K.-C., Chou, Y.-H., Wu, H., & Ou, H. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112995 · Cited by 15
Barana, L., De Fano, M., Cavallo, M., Manco, M., Prete, D., Fanelli, C. G., Porcellati, F., & Pippi, R. (2025) · Nutrients · doi:10.3390/nu18010131 · Cited by 13
Gjersdal, E., Klit, F. Ø., Ettrup, K. S., Vestergaard, P., Nielsen, E. H., Vistisen, K. N., Muller, H. L., Melgaard, D., & Dal, J. (2025) · Pituitary · doi:10.1007/s11102-025-01564-7 · Cited by 13
He, Z., Li, H., Zhang, Y., Gao, S., Liang, K., Su, Y., Wang, D., Yang, Z., Du, Y., Xing, D., et al. (2023) · Bioactive Materials · doi:10.1016/j.bioactmat.2023.12.007 · Cited by 13
Armutçu, F., & McCloskey, E. V. (2025) · Calcified Tissue International · doi:10.1007/s00223-025-01341-5 · Cited by 13
Picoli, C. C., Tsibulnikov, S., Ho, M., DeMambro, V., Feng, T., Eltahir, M., Le, P. T., Chlebek, C., Rosen, C. J., Ryzhov, S. V., et al. (2025) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00521.2024 · Cited by 13
Villegas-Martínez, I., Miguel-Elízaga, I. D., Carrasco-Torres, R., Marras, C., Canteras-Jordana, M., Yedra-Guzmán, M. J., Martínez-Villanueva, M., Conesa, D. T., & Martín-Fernández, J. (2016) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000199 · Cited by 13
Progress in the contrary effects of glucagon-like peptide-1 and chemerin on obesity development
Zhang, Q., Ye, J., & Wang, X. (2023) · Experimental Biology and Medicine · doi:10.1177/15353702231214270 · Cited by 13
Ali, A., Flatt, P. R., & Irwin, N. (2024) · Clinical Medicine Insights Endocrinology and Diabetes · doi:10.1177/11795514241238059 · Cited by 12
The “Burden” of Childhood Obesity on Bone Health: A Look at Prevention and Treatment
Farella, I., Chiarito, M., Vitale, R., D’Amato, G., & Faienza, M. F. (2025) · Nutrients · doi:10.3390/nu17030491 · Cited by 16
Maagensen, H., Helsted, M. M., Gasbjerg, L. S., Vilsbøll, T., & Knop, F. K. (2022) · Current Osteoporosis Reports · doi:10.1007/s11914-022-00767-2 · Cited by 14
The effects of GIP, GLP-1 and GLP-2 on markers of bone turnover: a review of the gut–bone axis
Longo, M., Mathiesen, D. S., Gasbjerg, L. S., Esposito, K., Lund, A., & Knop, F. K. (2025) · Journal of Endocrinology · doi:10.1530/joe-24-0231 · Cited by 12
Tummala, S., Gibbs, D. L., Chavarria, J. C., Alder, J., Avramis, I., & Rizkalla, J. (2025) · Journal of Orthopaedics · doi:10.1016/j.jor.2025.05.018 · Cited by 13
The effect of meals on bone turnover - a systematic review with focus on diabetic bone disease
Fuglsang-Nielsen, R., Starup‐Linde, J., Gregersen, S., & Vestergaard, P. (2018) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2018.1518131 · Cited by 11
Refaie, A. F. A., Baldassini, L., Mondillo, C., Gonnelli, S., Ceccarelli, E., Tarquini, R., Gonnelli, S., Gennari, L., & Caffarelli, C. (2025) · Endocrine · doi:10.1007/s12020-025-04253-4 · Cited by 11
Incretins today: multiple effects and therapeutic potential
Васильевна, Ц. О., Васильевна, В. В., & As, A. (2019) · Diabetes Mellitus · doi:10.14341/dm9841 · Cited by 11
Abildgaard, J., Ploug, T., Pedersen, A. T., Eiken, P., Pedersen, B. K., Holst, J. J., Hartmann, B., & Lindegaard, B. (2020) · Bone · doi:10.1016/j.bone.2020.115612 · Cited by 9
Self-citationAbildgaard, J., Johansen, M. Y., Skov‐Jeppesen, K., Andersen, L. B., Karstoft, K., Hansen, K. B., Hartmann, B., Holst, J. J., Pedersen, B. K., & Ried‐Larsen, M. (2021) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0000000000002776 · Cited by 8
Self-citationAcarbose diminishes postprandial suppression of bone resorption in patients with type 2 diabetes
Dalsgaard, N. B., Gasbjerg, L. S., Helsted, M. M., Hansen, L. S., Hansen, N. L., Skov‐Jeppesen, K., Hartmann, B., Holst, J. J., Vilsbøll, T., & Knop, F. K. (2023) · Bone · doi:10.1016/j.bone.2023.116687 · Cited by 9
Self-citationZhu, S., Gu, Y., Wang, W., Bai, J., Ge, G., Zhang, W., Wang, Q., Guo, X., Xiao, L., Tao, Y., et al. (2019) · PubMed Central · Cited by 9
Li, M., Xu, S., Cai, H., Xiao, J., & Qin, Y. (2026) · Metabolism · doi:10.1016/j.metabol.2026.156547 · Cited by 8
The Impact of Bariatric Surgery on Bone Health: State of the Art and New Recognized Links
Mendonça, F. M., Soares, R. A., Carvalho, D. M., & Freitas, P. (2022) · Hormone and Metabolic Research · doi:10.1055/a-1767-5581 · Cited by 8
Guo, H., Sui, C., Ge, S., Cai, J. Q., Lin, D., Guo, Y., Wang, N., Zhou, Y., Ying, R., Zha, K., et al. (2022) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3550 · Cited by 8
Goldman, S. N., Mani, K., Scharfenberger, T., Kleinbart, E. P., Hui, A. T., Ramos, R. D. L. G., Fourman, M. S., & Eleswarapu, A. S. (2025) · North American Spine Society Journal (NASSJ) · doi:10.1016/j.xnsj.2025.100612 · Cited by 9
The impact of semaglutide use for weight loss on transforaminal lumbar interbody fusion outcomes
Khalid, S. I., Mirpuri, P., Massaad, E., Wang, R., Elsamadicy, A. A., Shin, J. H., & Adogwa, O. (2025) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2025.108952 · Cited by 8
Antiobesity medications in rheumatology. Quo vadis?
Kyriazi, N., Vassilakis, K. D., Bakiri, A., Iliopoulos, A., & Fragoulis, G. (2025) · Annals of the Rheumatic Diseases · doi:10.1016/j.ard.2025.08.013 · Cited by 7
Comparison of Fracture Risk Following Semaglutide Treatment vs Sleeve Gastrectomy
Noreña, J. A., Pike, C. W., Hui, G., Motlaghzadeh, Y., Sellmeyer, D. E., Wu, J. Y., & Kim, S. H. (2025) · AACE Endocrinology and Diabetes · doi:10.1016/j.aed.2025.10.001 · Cited by 7
An, F., Song, J., Chang, W., Zhang, J., Gao, P., Wang, Y., Xiao, Z., & Yan, C. (2024) · Molecular Biotechnology · doi:10.1007/s12033-023-01018-0 · Cited by 7
Liraglutide, GLP-1 receptor agonist, for chronic weight loss
Moore, K. G., Shealy, K. M., & Clements, J. N. (2016) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2016.1220295 · Cited by 7
Kreitman, A., Schneider, S. H., Hao, L., Schlussel, Y., Bello, N. T., & Shapses, S. A. (2021) · Osteoporosis International · doi:10.1007/s00198-020-05791-5 · Cited by 7
McMath, A. L., & Gallagher, D. (2025) · Obesity Reviews · doi:10.1111/obr.70041 · Cited by 7
Kvist, A. V., Andersen, S. S., Vestergaard, P., & Viggers, R. (2026) · Osteoporosis International · doi:10.1007/s00198-026-07950-6 · Cited by 6
Ghoreishy, S. M., Noormohammadi, M., Zeraattalab-Motlagh, S., Shoaibinobarian, N., Rashedi, M. H., Movahed, S., Hemmati, A., Nazarian, A., Fernandez, M. L., & Shidfar, F. (2024) · Nutrition Reviews · doi:10.1093/nutrit/nuae128 · Cited by 6
Effect of incretins on skeletal health
Starup‐Linde, J., Hygum, K., & Langdahl, B. L. (2023) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000813 · Cited by 6
Sharma, A., Lieu, B. A., Velichala, S. R., Ernst, B. S., Satalich, J. R., Smith, M., & Golladay, G. J. (2025) · The Journal of Arthroplasty · doi:10.1016/j.arth.2025.08.073 · Cited by 5
The Effects of Obesity and Weight Loss Interventions on Bone Health: A Narrative Review
Palermo, A., Tsourdi, E. A., Yavropoulou, M. P., Naciu, A. M., Tabacco, G., Makras, P., Paccou, J., & Anastasilakis, A. D. (2025) · Current Diabetes Reports · doi:10.1007/s11892-025-01609-y · Cited by 5
Liraglutide reduces bone marrow adipogenesis by miR-150-5p/ GDF11 axis in diabetic rats
Wang, N., Lin, Z., Gao, L., Wang, B., Wei, K., Zhang, M., Li, Y., & Xue, P. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176793 · Cited by 5
Cheng, L., Xu, Y., Long, Y., Yu, F., Gui, L., Zhang, Q., & Lu, Y. (2023) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-023-02572-9 · Cited by 5
Mobasheri, A., Henriques, J., & Collins, J. E. (2025) · Osteoarthritis Imaging · doi:10.1016/j.ostima.2025.100374 · Cited by 4
Do GLP-1 agonists affect perioperative risk in spine surgery? A systematic review and meta-analysis
Ononogbu-Uche, F. C., Toussaint, F. S., Saleh, A. W., Siddig, A. H. E., Ahmed, R., Akl, K., Algabri, M. H., Alwadai, M. M., Corliss, L. E., Foster, N. A., et al. (2025) · North American Spine Society Journal (NASSJ) · doi:10.1016/j.xnsj.2025.100835 · Cited by 4
Mulcahy, J., DeLaRosby, A., & Norwood, T. (2025) · Physical Therapy · doi:10.1093/ptj/pzaf061 · Cited by 6
Engelbrechtsen, L., Iepsen, E. W., Galijatovic, E. A. A., Mahendran, Y., Lundgren, J. R., Jonsson, A. E., Madsbad, S., Holst, J. J., Vestergaard, H., Hansen, T. F., et al. (2016) · Metabolomics · doi:10.1007/s11306-016-1128-0 · Cited by 5
Self-citationKim, M. J., Kim, S., Jung, H. N., Jung, C. H., Lee, W. J., & Cho, Y. K. (2025) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes24009 · Cited by 4
Das, L., Bhadada, S. K., Arjunan, D., & Duseja, A. K. (2025) · Calcified Tissue International · doi:10.1007/s00223-025-01417-2 · Cited by 4
Xiang, S., Wan, J.-B., Jiang, X., Zhu, Y.-H., Ma, J., & Hua, F. (2016) · Medical Science Monitor · doi:10.12659/msm.896469 · Cited by 4
Conte, C., Cecere, A., Guglielmi, G., & Napoli, N. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-2970 · Cited by 4
Krogh, L. S. L., Helsted, M. M., Englund, A., Bergmann, N. C., Skov‐Jeppesen, K., Nielsen, C. K., Hansen, C. P., ROSENKILDE, M. M., Hartmann, B., Holst, J. J., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70186 · Cited by 3
Self-citationGastric bypass surgery mimetic approaches
Boettcher, B. R. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.04.009 · Cited by 3
Emerging incretin hormones actions: focus on bone metabolism
Grammatiki, M., Antonopoulou, V., & Kotsa, K. (2019) · Minerva Endocrinology · doi:10.23736/s0391-1977.19.03008-6 · Cited by 3
Effects of Hypoglycemic Agents on The Musculoskeletal System: A Comprehensive Review
Zhao, J., Lv, S.-S., Qi, L., Cong, X., & Zhang, X. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s517101 · Cited by 2
Goldstein, A. R., Olson, D., Leucht, P., Tejwani, N. C., Ganta, A., Konda, S. R., & Egol, K. A. (2025) · European Journal of Orthopaedic Surgery & Traumatology · doi:10.1007/s00590-025-04477-0 · Cited by 2
Yang, W., Hao, C., Wang, N., Xie, J., Zhou, B., Yang, Z., Zheng, A., Wei, J., Li, C., Xie, C., et al. (2026) · Gut Microbes · doi:10.1080/19490976.2026.2661854 · Cited by 3
Afsharian, Y. P., Rahimnejad, M., Rabiee, S. M., Feizi, F., & Seitz, H. (2025) · Advanced Therapeutics · doi:10.1002/adtp.202400400 · Cited by 2
Narrative Review of Perioperative Glucagon-like Peptide-1 (GLP-1) Agonists in Spine Surgery
Connelly, J. W., Narayanan, R., Ezeonu, T., Kothari, P., Spina, N., Spiker, W. R., Lawrence, B. D., Brodke, D. S., Schroeder, G. D., & Karamian, B. A. (2025) · Clinical Spine Surgery A Spine Publication · doi:10.1097/bsd.0000000000001888 · Cited by 2
Bariatric Surgery, Vitamin D, and Bone Loss
Tiffany Y, K., & Schafer, A. L. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-809963-6.00064-x · Cited by 2
Letter to the Editor: Liraglutide-Induced Increase in Bone Formation Can Be Dependent on Osteocalcin
Kızılgül, M., Kan, S., Beysel, S., & Delibaşı, T. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-2563 · Cited by 2
Diabetes, diabetic medications, and risk of fracture
D’Onofrio, L., Palermo, A., & Napoli, N. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-813073-5.00050-2 · Cited by 1
Baun, M. D., & Page, G. (2025) · Journal of the American Osteopathic Academy of Orthopedics · doi:10.70709/r2fykae2uu · Cited by 1
Hansen, J. V., Mathiesen, D. S., Christensen, M., Jørgensen, N. R., Helsted, M. M., Bagger, J. I., Holst, J. J., Vilsbøll, T., Knop, F. K., & Lund, A. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf482 · Cited by 1
Self-citationExtrapancreatic Effect of Glucagon like Peptide-1
Jeong, I. (2015) · Korean Journal of Medicine · doi:10.3904/kjm.2015.89.4.404 · Cited by 1
Impact of glucose-lowering medications on bone health in diabetes
Choksi, P. U., & Tan, M. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-820605-8.00004-8 · Cited by 1
Incretins Enhance PGF2α-Induced Synthesis of IL-6 and Osteoprotegerin in Osteoblasts
Hioki, T., Kuroyanagi, G., Fujita, K., Sakai, G., Kawabata, T., Kim, W. Y., Tachi, J., Matsushima‐Nishiwaki, R., Iida, H., Kozawa, O., et al. (2022) · Hormone and Metabolic Research · doi:10.1055/a-1713-7967 · Cited by 1
Response to the Letter by Napoli N., et al
Iepsen, E. W. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3142
Self-citationOsteoporose bei Diabetes mellitus
Tsourdi, E. A., & Hofbauer, L. C. (2021) · Diabetes aktuell · doi:10.1055/a-1508-3113
Therapeutic potential of zein-based nanoparticles
Reboredo, C. (2022) · doi:10.15581/10171/62894
Bariatric surgery, vitamin D, and bone loss
Kim, T. Y., & Schafer, A. L. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-91338-6.00009-4
Cheng, Y., Liu, P., Xiang, Q., Liang, J., Chen, H., Zhang, H., & Yang, L. (2022) · Figshare · doi:10.6084/m9.figshare.19785515
Vestergaard, P., & Viggers, R. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00084-4
Modulation of Bone Turnover Markers with Dipeptidyl Deptidase-4: Interplay in Bone Health
Ahmed, F., Ahmad, S. S., Najmi, A. K., & Khan, M. A. (2025) · Current Drug Therapy · doi:10.2174/0115748855339134250115052747
Influence of Omega-3 Fatty Acids on Energy Metabolism and Bone Turnover
Toledano, J. M., Puche-Juárez, M., Ochoa, J. J., Pulido‐Moran, M., Kajarabille, N., Díaz‐Castro, J., & Moreno‐Fernández, J. (2025) · Springer eBooks · doi:10.1007/978-3-031-84200-9_10
Playter, K. P., Chen, Y.-H., Grant, A. R., Chen, Y., Travers, H. I., Hollenbeck, B. L., Nin, D. Z., Niu, R., Talmo, C. T., Chang, D., et al. (2025) · Research Square · doi:10.21203/rs.3.rs-7490872/v1
New Antidiabetic Drugs: Effects on Bone
Orsi, E., & Resi, V. (2025) · Springer eBooks · doi:10.1007/978-3-032-01700-0_9
Brazilian guidelines for the management of osteoporosis in diabetes mellitus
de Paula, F. A., Silva, B. C. C., d’Alva, C. B., Ohe, M. N., Madeira, M., Farias, L. B. E., de Holanda, N. C. P., Gomes, N. D., Filho, R. L. D. S., Lauria, M. W., et al. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-02063-2
Khela, H. S., Kishan, A., Manriquez, A. H., Kirby, L., Chisango, Z. M., Carayannopoulos, N. L., Singh, M., Cottrill, E. J., Avedian, R. S., Kleck, C. J., et al. (2026) · Spine Open · doi:10.1097/bn9.0000000000000051
Bone changes after significant weight loss
Brunerová, L. (2025) · Clinical Osteology · doi:10.36290/clo.2025.031
Brady, A., Roopnarinesingh, R. C., Craig, R., & Bampoe, S. (2026) · Research Square · doi:10.21203/rs.3.rs-9197869/v1
Goldstein, A. R., Lashgari, A. M., Leucht, P., Ganta, A., Konda, S. R., & Egol, K. A. (2026) · The Journal of Knee Surgery · doi:10.1055/a-2851-0573
GLP-1 Agonists in Orthopedic Surgery: A Narrative Review of Bone Health and Surgical Implications
Mejia, M. R., Tiao, J., Yu, A., Baidya, J., Rajjoub, M., Torres, R. B., & Chaudhary, S. B. (2026) · HSS Journal® The Musculoskeletal Journal of Hospital for Special Surgery · doi:10.1177/15563316261438492 · Cited by 2
Zhang, L., Hu, J., Huang, C., Gao, X., Pang, D., & Duan, L. (2026) · Molecular Metabolism · doi:10.1016/j.molmet.2026.102390
Beyond Weight Loss: The Musculoskeletal Effects of GLP-1 Therapies
Zurowska, A. (2026) · EMJ Rheumatology · doi:10.33590/emjrheumatol/771475ds
Cathey, J. M., Fischer, J. P., Zhang, J., Hammert, W. C., Klifto, C. S., & Pidgeon, T. S. (2026) · Injury · doi:10.1016/j.injury.2026.113456
Unconventional Applications of Semaglutide and Tirzepatide: From Oncology to Human Reproduction
Vignera, S. L., & Condorelli, R. A. (2026) · Biomedicines · doi:10.3390/biomedicines14071644
Impact of glucagon-like peptide-1 receptor agonists on bone metabolism
Vadini, V., Duan, D., & Moseley, K. F. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag323 · Cited by 1
Yu, X., Wang, S., Lin, K., & Guan, J. (2026) · European Spine Journal · doi:10.1007/s00586-026-10293-9
Genetically Proxied GIP ‐ GIPR Pathway Perturbation and Fracture Risk
Cheng, W., Liu, W., Wei, J., Zeng, C., Lyu, H., & Zhao, S. S. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71378
The incretin-bone axis: molecular mechanisms and clinical implications
Muscarà, A., Bellone, F., & Rossi, M. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1907875
Metadata
- Authors
- Iepsen, E. W., Lundgren, J. R., Hartmann, B., Pedersen, O., Hansen, T., Jørgensen, N. R., Jensen, J.-E. B., Holst, J. J., Madsbad, S., & Torekov, S. S.
- Affiliations
- University of Copenhagen (DK)
- Corresponding author
- Iepsen, Eva W.
- Torekov, Signe S.
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2015-08
- Volume
- 100
- Issue
- 8
- Pages
- 2909-2917
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W1934495549
- Cited by
- 193
- References
- 54
- Citations by year
- 2026: 16 · 2025: 39 · 2024: 21 · 2023: 15 · 2022: 16 · 2021: 9 · 2020: 11 · 2019: 24 · 2018: 15 · 2017: 10 · 2016: 9 · 2015: 8
- FWCI
- 14.41
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Funders
- Danish Diabetes Academy
- Ministério da Ciência, Tecnologia e Inovação
- Novo Nordisk
- Copenhagen Graduate School for Nanoscience and Nanotechnology
- Faculty of Health and Medical Sciences, University of Western Australia
- Hvidovre Hospital
- Novo Nordisk Fonden (NNF14OC0009787)
- Det Sundhedsvidenskabelige Fakultet, Københavns Universitet
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- GLP-1 receptor agonists, liraglutide, bone loss, bone formation, weight loss, obesity, obese women, bone mineral content, bone turnover markers, P1NP, C-terminal telopeptide of type I collagen, hypocaloric diet, weight maintenance, glucagon-like peptide-1, osteoporosis prevention
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Liraglutide, Adolescent, Adult, Aged, Bone Resorption, Female, Humans, Middle Aged, Obesity, Osteogenesis, Weight Loss, Receptors, Glucagon, Caloric Restriction, Glucagon-Like Peptide 1, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
